Somewhere between “it’s not a stimulant” and “it’s not associated with abuse or euphoria,” a lot of the marketing conversation around Strattera skips right past a question that comes up constantly in real prescriber offices: will this medication change my weight, or my child’s? The honest answer is yes, it can — just not usually in the dramatic way stimulants are known for, and the pattern looks meaningfully different in children compared to adults.
This article walks through what’s actually driving the appetite and weight changes some people notice on Strattera (atomoxetine), how much change is typical, how it compares to what happens on a stimulant, and — importantly — what warrants a call to your prescriber rather than just watching and waiting
Why Strattera Affects Appetite in the First Place
Strattera isn’t marketed or studied as a weight-loss drug, but its mechanism of action overlaps with pathways known to influence appetite and energy regulation. As a selective norepinephrine reuptake inhibitor, atomoxetine increases norepinephrine activity throughout the body, not just in the brain regions tied to attention. Norepinephrine is part of the body’s sympathetic nervous system — the same system responsible for the “fight or flight” response — and elevated sympathetic activity is well-documented to suppress appetite and modestly increase resting energy expenditure. This is the same broad mechanism, incidentally, that led researchers to test atomoxetine specifically as a weight-loss aid in obese adults in a small clinical trial, separate from its ADHD use, with modest positive results — though it has never been approved or marketed for that purpose.
On top of this appetite-related mechanism, early gastrointestinal side effects — nausea, in particular — contribute to reduced food intake for some patients during the first few weeks of treatment, independent of any direct appetite-suppressing effect.
What the Clinical Data Actually Shows
In Children: A Documented, Monitored Pattern
The clearest data on Strattera and weight comes from pediatric studies, since growth monitoring is a standard part of long-term ADHD treatment in children. One notable one-year trial comparing atomoxetine to placebo in children with ADHD found that weight percentile (a child’s weight ranking compared to peers of the same age) decreased from an average of 52.3 to 48.4 in the atomoxetine group over the study period, while it increased from 53.1 to 58.5 in the placebo group — a statistically significant difference. Height percentile showed a similar, smaller pattern: a modest decrease in the atomoxetine group compared to a modest increase in the placebo group.
Importantly, these are population averages showing a relative slowdown in growth trajectory, not weight loss in the sense of a child shrinking or losing ground on the growth chart. Most children continue gaining weight and height on Strattera — just at a somewhat slower rate than would be expected without the medication, particularly in the first six to twelve months. Existing clinical literature and prescribing guidance generally describe this effect as tending to level out with continued treatment, which is why growth is tracked at regular intervals rather than assumed to be a one-time adjustment.
In Adults: Smaller and More Variable
Adult data is less centered on growth curves (since adults aren’t growing) and instead focuses on appetite and body weight directly. Adults on Strattera commonly report a reduction in appetite, particularly early in treatment, and a subset experience measurable but modest weight loss. Unlike children, where the effect is consistently documented across trials, adult experiences vary considerably — some adults notice minimal appetite change, while others notice a more pronounced reduction, particularly if they were prone to stress-related or emotional overeating before starting treatment, where improved impulse control itself may play a secondary role in reduced snacking or compulsive eating patterns.
How Strattera’s Weight Effect Compares to Stimulants
If you’ve researched ADHD medications at all, you’ve likely seen appetite suppression listed as a near-universal stimulant side effect. It’s worth understanding why Strattera’s effect tends to be gentler by comparison.
| Factor | Strattera (atomoxetine) | Stimulants (Adderall, Ritalin, etc.) |
|---|---|---|
| Mechanism | Selective norepinephrine reuptake inhibition | Broad dopamine and norepinephrine release |
| Typical appetite effect | Mild to moderate, gradual | Often more pronounced, especially during peak effect |
| Timing of appetite suppression | Fairly steady across the day given 24-hour coverage | Concentrated around dose peak, often easing by evening |
| Typical pattern over time | Tends to soften with continued treatment | Can persist longer-term, especially at higher doses |
| Use in children | Requires growth monitoring; effect on growth curve is measurable but modest | Also requires growth monitoring; appetite suppression is generally more pronounced |
This is one of the reasons some prescribers steer toward Strattera specifically for patients — children and adults alike — who struggled significantly with appetite suppression or weight loss on a stimulant. For the fuller picture of how these two treatment categories compare across the board, see our guide to Strattera vs. Adderall.
The Timeline: When Appetite Changes Typically Appear and Fade
- Weeks 1-2: If appetite suppression is going to occur, it commonly begins here, sometimes alongside early nausea as the body adjusts to the medication.
- Weeks 2-8: This is generally when appetite effects are most noticeable, overlapping with the window when Strattera’s main therapeutic benefit is also building — a timeline we cover in detail in How Long Does Strattera Take to Work?
- Months 3-12: For many patients, appetite gradually normalizes during this period, even as the medication’s ADHD-related benefits continue to strengthen. This is consistent with the growth-curve data in children, which describes the growth-rate slowdown as generally leveling out with continued treatment.
Practical Strategies If Strattera Is Suppressing Appetite
Whether the patient is a child or an adult, a few practical approaches are commonly discussed with prescribers when appetite suppression becomes a noticeable, unwanted side effect:
- Take the dose with food. Beyond reducing nausea, eating alongside the dose can help establish a habit of eating even when hunger cues are blunted.
- Front-load nutrition earlier in the day if appetite tends to dip later, prioritizing a substantial breakfast and lunch when hunger is more likely to be present.
- Focus on nutrient-dense foods rather than volume, especially in children, so that a smaller overall intake still meets nutritional needs.
- Track weight and, in children, height at regular intervals — not to obsess over small fluctuations, but to give your prescriber objective data at follow-up visits rather than a general impression.
- Consider timing adjustments, discussed with your prescriber, if appetite suppression is concentrated around a specific part of the day; our companion article on the best time to take Strattera covers how morning versus evening dosing can shift side effect timing.
When Weight Loss on Strattera Warrants a Doctor’s Visit
Mild, gradually improving appetite suppression is a known and generally manageable side effect. A few patterns, however, are worth flagging proactively rather than waiting for a routine follow-up:
- Weight loss that is rapid, significant, or continues without leveling off past the first few months of treatment.
- A child falling off their established growth curve — dropping multiple percentile lines on a standardized growth chart — rather than showing the more modest, expected slowdown.
- Signs of an eating pattern that feels disordered, rather than simply reduced hunger — this is especially important to watch for in adolescents.
- Weight loss accompanied by other concerning symptoms, such as persistent fatigue, dizziness, or gastrointestinal symptoms beyond mild, early nausea.
In any of these cases, your prescriber has several options: adjusting the dose, changing the timing, adding structured nutritional support, or, if needed, reconsidering whether Strattera remains the right medication.
Does Weight Return to Normal After Stopping Strattera?
For most patients, appetite and weight patterns return toward baseline after discontinuing Strattera, following a similar general timeline to how the medication’s therapeutic effects fade once the drug clears the body. In children whose growth had slowed somewhat during treatment, catch-up growth is a commonly described pattern after stopping or adjusting the medication, though the exact trajectory varies by individual and is best assessed by a pediatrician tracking growth data over time rather than assumed from population averages alone.
Could Strattera Ever Be Used Intentionally for Weight Management?
It’s worth being direct about this, since the mechanism naturally invites the question: Strattera is not FDA-approved for weight loss, and it should never be requested or used off-label specifically to lose weight. A small controlled trial did study atomoxetine’s effect in obese adults outside the ADHD context, and found a modest weight-loss benefit compared to placebo over 12 weeks — but this was a preliminary research study, not an approved use, and off-label use for weight management carries real risks, including cardiovascular effects and the same monitoring requirements that apply to its approved ADHD use, without the benefit of dedicated safety data for that purpose. If weight management is a goal alongside ADHD treatment, that’s a conversation to have directly and transparently with your prescriber, not a reason to pursue the medication independently.
Weight Loss vs. Appetite Suppression: Why the Distinction Matters
It’s worth separating two things that often get discussed as if they’re the same: appetite suppression (feeling less hungry) and weight loss (an actual measurable change on the scale). Appetite suppression is a much more consistently reported effect of Strattera than clinically significant weight loss is. Many patients notice they’re simply not as hungry, or forget to eat during a busy day, without ever losing a meaningful amount of weight — because reduced appetite on any given day doesn’t automatically translate into a caloric deficit large enough to show up as weight change, especially if meals, even if smaller, remain reasonably consistent. Understanding this distinction can help set more realistic expectations: most people should expect some possibility of reduced appetite, while fewer will experience weight loss significant enough to be a standalone concern.
A Closer Look at the Research on Atomoxetine and Body Weight
Beyond the pediatric growth-curve data already discussed, atomoxetine’s appetite-suppressing properties have attracted separate research interest specifically because of the norepinephrine pathway involved. A Duke University-affiliated randomized, double-blind, placebo-controlled trial examined atomoxetine specifically in obese adult women (average BMI around 36) over 12 weeks, titrating the dose from 25 mg up to 100 mg daily alongside a modest calorie-reduced diet. The study’s purpose wasn’t to support ADHD use — it was investigating atomoxetine’s norepinephrine-driven mechanism as a potential weight-management approach in its own right, separate from any ADHD diagnosis. While the results supported the idea that atomoxetine’s mechanism can measurably affect body weight, this research does not establish weight loss as an approved or intended outcome for ADHD patients — it simply helps explain, mechanistically, why appetite and weight changes are a plausible and documented side effect rather than a coincidence.
Nutritional Strategies for Parents Managing a Child’s Appetite Changes
Because children can’t always articulate hunger cues or nutritional needs the way adults can, parents managing a child on Strattera often benefit from more structured approaches:
- Offer the largest meal of the day at breakfast, before the medication’s appetite-suppressing effect has fully set in, since morning hunger is often more reliable than midday or evening appetite.
- Keep nutrient-dense snacks readily available — items like cheese, nut butter, yogurt, or smoothies — that pack more nutrition into a smaller volume than a child might otherwise be willing to eat.
- Avoid pressuring a child to finish meals when appetite is genuinely reduced by the medication, which can create negative associations with eating that outlast the medication’s effect.
- Keep a simple running log of weight measurements between pediatrician visits if growth is a particular concern, so patterns are easier to discuss objectively at appointments.
- Loop in a pediatric dietitian if appetite suppression is significant or prolonged — this is a reasonable, commonly used resource rather than an extreme step.
A Realistic Scenario
Consider a 9-year-old starting Strattera at a weight-based starter dose. In the first two weeks, their parents notice they’re eating noticeably less at dinner and skipping the usual after-school snack, alongside some mild stomach upset that improves after the first week. By the two-month pediatrician visit, weight gain has continued but at a slower pace than the child’s prior growth trend, moving them from roughly the 55th percentile to the 50th percentile for weight — a modest shift the pediatrician describes as within the expected, monitored range, not a cause for immediate concern. The family adjusts by front-loading a larger breakfast and offering higher-calorie snacks in the afternoon. By the six-month visit, appetite has largely normalized, and growth has returned closer to the original trend line. This kind of gradual, monitored pattern is far more typical than the alternative — a child in genuine caloric distress — which is a much less common scenario and one that would prompt a more immediate treatment change.
How Prescribers Decide Whether Appetite Changes Are a Problem
Not every reduction in appetite calls for a treatment change, and prescribers generally weigh several factors together rather than reacting to a single data point:
- Trajectory, not a single measurement. A slight dip at one visit is far less concerning than a consistent downward trend across several visits.
- Overall clinical picture. Energy levels, mood, sleep, and physical activity all factor in alongside the number on the scale or growth chart.
- Balance against treatment benefit. If ADHD symptoms are responding well and appetite changes are mild and stable, many prescribers and families choose to continue treatment with monitoring rather than switching medications over a modest effect.
- Patient and family input. How disruptive the appetite change feels day-to-day matters as much as the numbers themselves — two children with similar growth-chart shifts might warrant different responses depending on how each family is experiencing it.
This is why regular follow-up visits matter more than any single early appointment: appetite and weight patterns on Strattera are best understood as a trend to track, not a one-time side effect to check off a list.
Frequently Asked Questions
Is weight loss on Strattera a sign the medication is working?
No — appetite suppression and any related weight loss are separate from Strattera’s therapeutic effect on ADHD symptoms, which builds through a different mechanism over several weeks. One doesn’t predict or confirm the other.
Does everyone lose weight on Strattera?
No. Many patients, particularly adults, notice little to no appetite or weight change. When it does occur, the effect is usually mild to moderate rather than dramatic, and it varies significantly from person to person.
Can Strattera cause weight gain instead?
Weight gain is not a commonly reported effect of Strattera itself. If weight gain occurs during treatment, it’s worth discussing with your prescriber, since it may relate to appetite normalizing after an initial suppressed period, reduced physical activity, or factors unrelated to the medication.
Should my child stop taking Strattera if their growth slows slightly?
Not necessarily — a modest, monitored slowdown in growth rate is a recognized and generally expected pattern that clinical guidance describes as often leveling out over time. Whether to adjust the dose, pause treatment, or continue depends on the specific growth pattern and should be decided with your child’s prescriber based on ongoing growth chart tracking.
How is growth monitored for children on Strattera?
Prescribers typically track height and weight at baseline and at regular follow-up visits, plotting them on standardized pediatric growth charts to assess percentile trends over time rather than relying on single measurements in isolation.
Does the dose of Strattera affect how much appetite suppression occurs?
Generally yes — higher doses are more likely to produce noticeable appetite suppression than lower ones, which is part of why titration schedules are gradual and why a dose adjustment is one of the first strategies prescribers consider if appetite loss becomes a significant concern.
The Bottom Line
Strattera can suppress appetite and cause mild weight loss in some patients, and can modestly slow the rate of growth in children — effects rooted in its norepinephrine-driven mechanism and documented in clinical trials. For most people, this effect is manageable, tends to soften over the first several months, and is generally less pronounced than what’s typically seen with stimulant ADHD medications. Still, it’s a real physiological effect worth monitoring with regular check-ins, particularly for children, rather than dismissing as inconsequential or assuming it will resolve entirely on its own.
